Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study by Hamill, V, Wong, S, Benselin, J, Krajden, M, Hayes, PC, Mutimer, D, Yu, A, Dillon, JF, Gelson, W, Velásquez García, HA, Yeung, A, Johnson, P, Barclay, ST, Alvarez, M, Toyoda, H, Agarwal, K, Fraser, A, Bartlett, S, Aldersley, M, Bathgate, A, Binka, M, Richardson, P, Morling, JR, Ryder, SD, Barnes, E

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis by Fan, R, Papatheodoridis, G, Sun, J, Innes, H, Toyoda, H, Xie, Q, Mo, S, Sypsa, V, Guha, IN, Kumada, T, Niu, J, Dalekos, G, Yasuda, S, Barnes, E, Lian, J, Suri, V, Idilman, R, Barclay, ST, Dou, X, Berg, T, Hayes, PC, Flaherty, JF, Zhou, Y, Zhang, Z, Buti, M, Hutchinson, SJ, Guo, Y, Calleja, JL, Lin, L, Zhao, L, Chen, Y, Janssen, HLA, Zhu, C, Shi, L, Tang, X, Gaggar, A, Wei, L, Jia, J, Irving, WL, Johnson, PJ, Lampertico, P, Hou, J